Xenon Net Debt vs Other Current Liab Analysis
| XENE Stock | USD 42.97 1.09 2.60% |
Xenon Pharmaceuticals financial indicator trend analysis is more than just analyzing Xenon Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xenon Pharmaceuticals is a good investment. Please check the relationship between Xenon Pharmaceuticals Net Debt and its Other Current Liab accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.
Net Debt vs Other Current Liab
Net Debt vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Xenon Pharmaceuticals Net Debt account and Other Current Liab. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Xenon Pharmaceuticals' Net Debt and Other Current Liab is -0.62. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Xenon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Xenon Pharmaceuticals' Net Debt and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Xenon Pharmaceuticals are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Net Debt i.e., Xenon Pharmaceuticals' Net Debt and Other Current Liab go up and down completely randomly.
Correlation Coefficient | -0.62 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Other Current Liab
Most indicators from Xenon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xenon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.At present, Xenon Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 2.2 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 2.65.
Xenon Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Xenon Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Xenon Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Common Stock Shares Outstanding | 25.9M | 34.5M | 43.6M | 60.5M | 66.9M | 70.2M | |
| Total Assets | 147.7M | 189.2M | 572.0M | 754.1M | 964.8M | 1.0B | |
| Short Long Term Debt Total | 16.5M | 3.3M | 8.3M | 10.4M | 10.9M | 10.0M | |
| Other Current Liab | 6.3M | 7.8M | 9.9M | 13.7M | 17.4M | 18.2M | |
| Total Current Liabilities | 43.4M | 14.8M | 14.3M | 22.7M | 27.3M | 17.3M | |
| Total Stockholder Equity | 92.0M | 171.4M | 550.0M | 721.5M | 927.9M | 974.3M | |
| Property Plant And Equipment Net | 2.6M | 6.9M | 12.5M | 16.9M | 18.8M | 19.8M | |
| Net Debt | (8.3M) | (41.7M) | (167.4M) | (46.8M) | (137.7M) | (130.9M) | |
| Retained Earnings | (249.7M) | (278.5M) | (357.4M) | (482.7M) | (665.1M) | (631.9M) | |
| Accounts Payable | 2.5M | 3.0M | 3.8M | 8.5M | 8.6M | 9.0M | |
| Cash | 24.8M | 45.0M | 175.7M | 57.2M | 148.6M | 156.1M | |
| Non Current Assets Total | 2.8M | 7.4M | 13.0M | 153.8M | 319.8M | 335.8M | |
| Non Currrent Assets Other | 2.6M | 7.4M | 8.1M | 7.8M | 7.4M | 7.8M | |
| Cash And Short Term Investments | 141.4M | 177.0M | 551.8M | 592.1M | 638.1M | 670.0M | |
| Net Receivables | 813K | 1.8M | 2.8M | 986K | 874K | 872.3K | |
| Common Stock Total Equity | 294.2M | 397.7M | 783.2M | 1.1B | 1.2B | 1.3B | |
| Liabilities And Stockholders Equity | 147.7M | 189.2M | 572.0M | 754.1M | 964.8M | 1.0B | |
| Non Current Liabilities Total | 12.3M | 3.1M | 7.7M | 9.9M | 9.6M | 7.2M | |
| Other Current Assets | 2.7M | 3.0M | 4.5M | 7.2M | 6.0M | 6.3M | |
| Other Stockholder Equity | 40.6M | 45.4M | 117.5M | 142.1M | 156.8M | 164.6M | |
| Total Liab | 55.7M | 17.8M | 22.0M | 32.6M | 36.9M | 27.2M | |
| Total Current Assets | 144.9M | 181.8M | 559.0M | 600.3M | 645.0M | 677.2M | |
| Common Stock | 294.2M | 397.7M | 783.2M | 1.1B | 1.4B | 1.5B | |
| Property Plant Equipment | 1.7M | 3.6M | 4.5M | 6.5M | 7.5M | 7.8M | |
| Net Tangible Assets | 84.2M | 163.6M | 542.3M | 721.5M | 829.7M | 871.2M | |
| Other Assets | 238K | 523K | 465K | 143.7M | 306.2M | 321.5M | |
| Short Term Investments | 116.6M | 132.0M | 376.1M | 534.8M | 489.4M | 513.9M | |
| Retained Earnings Total Equity | (249.7M) | (278.5M) | (357.4M) | (482.7M) | (434.5M) | (412.7M) | |
| Capital Surpluse | 40.6M | 45.4M | 117.5M | 142.1M | 163.4M | 171.6M | |
| Net Invested Capital | 99.8M | 163.6M | 542.3M | 721.5M | 927.9M | 974.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Quarterly Revenue Growth (1.00) | Return On Assets (0.19) | Return On Equity (0.27) |
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.